September 4th 2020
The Melanoma Institute Australia nomogram was found to accurately estimate the risk of sentinel node metastasis positivity in patients with melanoma and its use could help to reduce the rate of unnecessary invasive biopsies without sacrificing sensitivity.
September 3rd 2020
Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.
August 29th 2020
When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?
August 28th 2020
Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
Mattia Garutti, MD, discusses the advantages of neoadjuvant therapy, predictive biomarkers under exploration, and future neoadjuvant clinical trial development.
August 24th 2020
Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.
Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.
August 20th 2020
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
August 19th 2020
Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.
Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.
